361441-95-4

Basic information

• Product Name: Tricyclo[3.3.1.13,7]decane-1-acetonitrile,.alpha.S)-
• Synonyms: (2S)-2-(Adamantan-1-yl)-2-(((R)-2-hydroxy-1-phenylethyl)amino)acetonitrile;1-(S)-adamantan-1-yl-(R)-(2-hydroxy-1-phenylethylamino)acetonitrile;Tricyclo[3.3.1.13,7]decane-1-acetonitrile,.alpha.S)-;Tricyclo[3.3.1.13,7]decane-1-acetonitrile, .alpha.- [[(1R)-2-hydroxy-1-phenylethyl]aMino]-, (.alpha.S)-;(alphaS)-alpha-[[(1R)-2-Hydroxy-1-phenylethyl]aMino]-tricyclo[3.3.1.1(3,7)]decane-1-acetonitrile
• CAS NO: 361441-95-4
• Molecular Formula: C₂₀H₂₆N₂O
• Molecular Weight: 310.43324
• EINECS: -0
• Mol File: 361441-95-4.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 511.0±35.0 °C at 760 mmHg
• Flash Point: 262.8±25.9 °C
• Appearance: /
• Density: 1.2±0.1 g/cm³
• PKA: 14.35±0.10(Predicted)
• CAS DataBase Reference: Tricyclo[3.3.1.13,7]decane-1-acetonitrile,.alpha.S)-(CAS DataBase Reference)
• NIST Chemistry Reference: Tricyclo[3.3.1.13,7]decane-1-acetonitrile,.alpha.S)-(361441-95-4)
• EPA Substance Registry System: Tricyclo[3.3.1.13,7]decane-1-acetonitrile,.alpha.S)-(361441-95-4)

Safety Data

• Hazardous Substances Data: 361441-95-4(Hazardous Substances Data)

Usage

General Description

Tricyclo[3.3.1.13,7]decane-1-acetonitrile, .alpha.S)- is a chemical compound with a tricyclic structure consisting of a six-membered ring fused to a three-membered ring. It is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals. The compound is an acetonitrile derivative with a stereocenter at the alpha position. Its unique structure and stereochemistry make it an important intermediate in the production of various organic compounds. The chemical has potential applications in medicinal chemistry and drug development due to its versatile reactivity and structural properties. Additionally, its stability and compatibility with a wide range of reaction conditions further enhance its utility as a key synthetic building block.

Upstream product

• 2094-74-8 1-Adamantanecarbaldehyde 
• 56613-80-0 D-2-phenylglycinol 
• 773837-37-9 sodium cyanide 
• 151-50-8 potassium cyanide 
• 711-01-3 methyl adamantane-1-carboxylate 
• 828-51-3 1-Adamantanecarboxylic acid 
• 770-71-8 1-adamantanemethanol 

Downstream Products

• 102502-64-7 (S)-(+)-(adamant-1-yl)aminoacetic acid hydrochloride 
• 1564265-93-5 saxagliptin 
• 361441-97-6 (alpha S)-alpha-[[(1,1-dimethylethoxy)carbonyl]amino]tricyclo[3.3.1.1^3,7]decane-1-acetic acid 
• 361442-01-5 tert-butyl [(1S)-2-[(1S,3S,5S)-3-carbamoyl-2-azabicyclo[3.1.0]hex-2-yl]-1-(3-hydroxytricyclo[3.3.1.1³'⁷]dec-1-yl)-2-oxoethyl]carbamate 
• 709031-43-6 3-cyano-(αS)-α-(3-hydroxytricyclo[3.3.1.1^3,7]dec-1-yl)-β-oxo-(1S,3S,5S)-2-azabicyclo[3.1.0]hexane-2-ethanecarbamic acid 1,1-dimethylethyl ester 
• 681282-72-4 (S)-2-((tert-butoxycarbonyl)amino)-2-(3,5-dihydroxyadamantan-1-yl)acetic acid 
• 361442-00-4 (αS)-α-[[(1,1-dimethylethoxy)carbonyl]-amino]-3-hydroxytricyclo[3.3.1.1^3,7]decane-1-acetic acid 

Relevant articles and documents

CFTR-MODULATING ARYLAMIDES

The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

Rapid Asymmetric Synthesis of Disubstituted Allenes by Coupling of Flow-Generated Diazo Compounds and Propargylated Amines

We report herein the asymmetric coupling of flow-generated unstabilized diazo compounds and propargylated amine derivatives, using a new pyridinebis(imidazoline) ligand, a copper catalyst and base. The reaction proceeds rapidly, generating chiral allenes in 10–20 minutes with high enantioselectivity (89–98 % de/ee), moderate yields and a wide functional group tolerance.

Synthesis and biological evaluation of all eight stereoisomers of DPP-IV inhibitor saxagliptin

All eight stereoisomers of saxagliptin have been synthesized and evaluated for their inhibitory activity against DPP-IV. It was unambiguously confirmed that the configuration of saxagliptin was critical to potent inhibition of DPP-IV. Docking study was performed to elucidate the configuration-activity relationship of saxagliptin stereoisomers. Tyr662 and Tyr470 have been suggested as the key residues of DPP-IV interacting with the inhibitors. This work provides valuable information for further inhibitor design against DPP-IV.